Next Article in Journal
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C
Next Article in Special Issue
Development of CMX001 for the Treatment of Poxvirus Infections
Previous Article in Journal
Profound Differences in Virus Population Genetics Correspond to Protection from CD4 Decline Resulting from Feline Lentivirus Coinfection
Previous Article in Special Issue
Development of ST-246® for Treatment of Poxvirus Infections
Open AccessReview

Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246

Department of Pediatrics, School of Medicine, The University of Alabama, 170 Children’s Harbor Building, 1600 6th Avenue South, Birmingham, Birmingham, AL 35233, USA
Author to whom correspondence should be addressed.
Viruses 2010, 2(12), 2681-2695;
Received: 8 November 2010 / Revised: 6 December 2010 / Accepted: 6 December 2010 / Published: 13 December 2010
(This article belongs to the Special Issue Antivirals Against Poxviruses)
Although a large number of compounds have been identified with antiviral activity against orthopoxviruses in tissue culture systems, it is highly preferred that these compounds have activity in vivo before they can be seriously considered for further development. One of the most commonly used animal models for the confirmation of this activity has been the use of mice infected with either vaccinia or cowpox viruses. These model systems have the advantage that they are relatively inexpensive, readily available and do not require any special containment facilities; therefore, relatively large numbers of compounds can be evaluated in vivo for their activity. The two antiviral agents that have progressed from preclinical studies to human safety trials for the treatment of orthopoxvirus infections are the cidofovir analog, CMX001, and an inhibitor of extracellular virus formation, ST-246. These compounds are the ones most likely to be used in the event of a bioterror attack. The purpose of this communication is to review the advantages and disadvantages of using mice infected with vaccinia and cowpox virus as surrogate models for human orthopoxvirus infections and to summarize the activity of CMX001 and ST-246 in these model infections.
Keywords: vaccinia virus; cowpox virus; murine model; orthopoxvirus; antiviral vaccinia virus; cowpox virus; murine model; orthopoxvirus; antiviral
MDPI and ACS Style

Quenelle, D.C.; Kern, E.R. Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246. Viruses 2010, 2, 2681-2695.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop